Therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits)

Recommendation ID: DG22/1
Question: Further research into the analytical and clinical validity of the enzyme-linked immunosorbent assay (ELISA) kits (LISA-TRACKER, IDKmonitor and Promonitor) is recommended, specifically on:
- the best methods to measure tumour necrosis factor (TNF)-alpha-inhibitor levels in the presence of antibodies to TNF-alpha inhibitors
- developing primary reference standards
- the accuracy for predicting clinical state
- clinically meaningful thresholds.
Any explanatory notes (if applicable): None

Source guidance details

Comes from guidance: Therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits)
Number: DG22
Date issued: February 2016

Is this a recommendation for the use of a technology only in the context of research?	No
Is it a recommendation that suggests collection of data or the establishment of a register?	No
Last Reviewed	29/02/2016